Phase 2 Mutations Clinical Trials
21 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 21 trials
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 2
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164
Recruiting
Phase 2Phase 3
Spironolactone Improved Children With Gene Mutations Related to NCOR
ASDNCOR Gene MutationsSpironolactone
Qilu Hospital of Shandong University2 enrolled1 locationNCT06678685
Recruiting
Phase 1Phase 2
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Regeneron Pharmaceuticals30 enrolled16 locationsNCT05788536
Recruiting
Phase 1Phase 2
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.18 enrolled1 locationNCT07429240
Recruiting
Phase 2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Targeted TherapyIDH1-Mutated MalignanciesMutations
M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727
Recruiting
Phase 1Phase 2
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations
Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Shanghai Euhearing Therapeutics Co., Ltd30 enrolled1 locationNCT07288580
Recruiting
Phase 2
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital74 enrolled1 locationNCT07505173
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Colorectal, CancerPancreatic CancerMetastatic Solid Tumor+5 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Recruiting
Phase 2
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Pancreatic Ductal Adenocarcinoma (PDAC)KRAS G12D Mutations
Ranok Therapeutics (Hangzhou) Co., Ltd.60 enrolled2 locationsNCT07303465
Recruiting
Phase 1Phase 2
Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Phase 1Phase 2
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502
Not Yet Recruiting
Phase 2
Efficacy of assigning treatment for participants with VEXAS syndrome with lenzilumab plus azacitidine
V - vacuoles are often seen in cells identified in bone marrow biopsies from patients with VEXAS syndrome.
E - E1 ubiquitin activating enzyme, encoded by the UBA1 gene which is mutated in patients
X - the UBA1 gene is located on the X chromosome.
A - patients have autoinflammation.
S - the mutations are somatic, meaning they are acquired at some point in life and not inherited.
(VEXAS)
South Australian Health & Medical Research Institute Ltd10 enrolled1 locationACTRN12625000619448
Recruiting
Phase 2
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Arterial calcificationPseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency+2 more
Inozyme Pharma200 enrolled5 locationsNCT06462547
Recruiting
Phase 1Phase 2
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.20 enrolled3 locationsNCT05906953
Recruiting
Phase 1Phase 2
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
Advanced Solid Tumors With MAPK Signal Pathway Mutations
Suzhou Genhouse Bio Co., Ltd.110 enrolled1 locationNCT06310382
Recruiting
Phase 1Phase 2
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Advanced Solid TumorNon-small Cell Lung CancerHER2 Mutations
Anbogen Therapeutics, Inc.61 enrolled5 locationsNCT05532696
Recruiting
Phase 2
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Li-Fraumeni SyndromePediatric Cancerp53 Mutations
Yang Li50 enrolled1 locationNCT06088030